Ireland Archives

News and Trends 18 Oct 2016

Shire’s leading Pancreatic Cancer drug is Back with a Bang

Pancreatic cancer is one of the nastiest kinds and most difficult to treat; the EMA has granted marketing authorization to Onivyde in the fight against it. Pancreatic cancer is the fourth-leading cause of death in Europe, and it represents a dramatically underserved need. Metastatic adenocarcinoma is almost always fatal, as it cannot be removed surgically […]

October 18, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 14 Sep 2016

Novartis invests in Irish Upstart tackling Chronic Inflammation

Dublin-based Inflazome has made a splashy debut by closing Series A with €15M. The company will use these funds to develop therapies targeting inflammasome-based chronic diseases. Chronic inflammation might sound like a minor livable irritation, but it can be deadly. Think Multiple Sclerosis, Rheumatoid Arthritis, and Lupus. It’s also one of the most lucrative fields […]

September 14, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 13 Sep 2016

Horizon Pharma successfully negotiates Acquisition of US Competitor for €712M

Perhaps having learned from its Depomed debacle last year, Horizon Pharma has lined up a successful acquisition of another competitor, Raptor Pharmaceuticals, for €712M ($800M). Last summer, the Irish company, Horizon Pharma, wouldn’t take no for an answer in its overtures to acquire Depomed, an American speciality pharmaceutical company. It was rejected not once but twice, […]

September 13, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 8 Sep 2016

Allergan seizes visionary Optogenetic Therapy from US Startup

Allergan is diving into gene therapy with the acquisition of RetroSense Therapeutic’s new early clinical candidate, RST-001. The drug aims to remedy Retinitis Pigmentosa, which affects between 13 and 44 in 100k people worldwide. Allergan has just acquired RetroSense Therapeutics as part of their ongoing effort in eye care. The core of the deal was […]

September 8, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 15 Aug 2016

These 3 Synbio Startups did a ‘perfect pitch’ at IndieBio’s Demo Day

On July 28th 2016, IndieBio EU, the world’s first biotech accelerator, held their demo day in the lovely surroundings of Cork City Gaol. On the night, 13 startups pitched their ideas and products in the hopes of securing investment to take their ideas to the next level. Firebreathers and a live band added the finishing touch to […]

August 15, 2016 - 4 minutesmins - By Denise Neves Gameiro

indiebio eu 2016 synthetic biology accelerator

News and Trends 16 Jun 2016

Europe’s Leading SynBio Incubator has 13 new Biotechs ready to Hatch

IndieBio is an accelerator program for new ideas in Synthetic Biology. The participants of the most recent edition (Summer 2016) have been hard at work in Ireland since May 3rd – and now you can take a peek at what’s going on. The objective of IndieBio‘s program is to unlock the creative potential of students, researchers or […]

June 16, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 23 May 2016

Irish NASH drug will also be investigated for Major Lung Diseases

DS Biopharma was already studying one of its bioactive lipids for non-alcoholic steatohepatitis (NASH). The candidate will now also target chronic obstructive pulmonary disease (COPD). Headquartered in Dublin (Ireland), DS Biopharma is working on new medicines for medical unmet needs, such as fibrosis. This development of fibrous tissue can affect the lungs, liver or heart. DS has […]

May 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr charpentier ers genomics bayer blsc

News and Trends 18 May 2016

Bayer claims CRISPR Patents for Gene-Editing Agreements

Bayer has signed a patent license agreement with ERS Genomics, that controls patents for the CRISPR-Cas9 system – a breakthrough gene-editing technology. Bayer Lifescience Center (BLSC) is the innovation division of German Giant Bayer, which aims to address challenges in the pharmaceutical and agro-industry. Its strategy is to establish collaborations with innovative Biotechs, and create a […]

May 18, 2016 - 2 minutesmins - By Denise Neves Gameiro

center genomic gastronomy denfeld kramer

News and Trends 9 Apr 2016

BioArt & Genomic Gastronomy: Glowing Sushi, ‘Smog Tasting’ and Gamma Gardens

The Center for Genomic Gastronomy in Dublin (Ireland) curates an unusual type of BioArt which makes us think about how we see food and technology – through fluorescent sushi, ‘Smog candy’ and radiation-bred sauces. Describing themselves as an ‘artist-led think tank‘, the Center for Genomic Gastronomy (CGG for short) is making witty projects that range from cook-offs and […]

April 9, 2016 - 5 minutesmins - By Denise Neves Gameiro

heptares allergan neurological alzheimer gpcr

News and Trends 7 Apr 2016

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer’s, to Allergan for up to €3Bn. A good way for Allergan to ‘get over’ yesterday’s failed Pfizer acquisition. Based in Cambridge, UK, Heptares Therapeutics is creating new therapies with their StaR platform, that allows it to target G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to many […]

April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 21 Mar 2016

Ferment the Next Bio-Revolution with IndieBio Accelerator

IndieBio is an accelerator program for new ideas in Synthetic Biology – to transform them into startups during a Summer in Ireland. The potential of Synthetic Biology ranges from biofuels to perfumes to healthcare – and it will be at the forefront of the biotechnological revolution. The concept is already implemented by big Biotechs (with a big presence in France) […]

March 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

spark therapeutics genable gene therapy blindness pigmentosa rhonova

News and Trends 8 Mar 2016

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy for a degenerative eye disease which progresses to blindness. Spark Therapeutics is one of the players in the re-emerging field of Gene Therapy (which is already establishing records like the most expensive drug). It focuses on debilitating genetic diseases, like inherited […]

March 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us